Trial Profile

Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2022 Results(n=155) assessing the Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity published in the Diabetes, Obesity and Metabolism
23 Sep 2022 Results of exploratory analysis assessing effects on glucose metabolism and glycaemic status(normoglycaemia; prediabetes; T2D) at week 68, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes..
11 Jan 2022 Protocol was amended to allow the subjects to continue in the trial, while also participating in a COVID-19 trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com